Key takeaways
- 7,000–10,000 Estimated UK generalised MG (gMG) patient population
- ~4,000 UK moderate-severe gMG patients not on any NICE-approved novel therapy
- 30–40% UK gMG patients with inadequate disease control on current standard therapy (MGA UK survey 2023)
UK generalised myasthenia gravis has no NICE-recommended novel agent — efgartigimod's June 2025 rejection (TA1069) leaves the 30-centre NHS neuromuscular network without a positive access decision.
Myasthenia gravis is an autoimmune disorder of the neuromuscular junction, most commonly driven by AChR antibodies (85% of generalised MG), with anti-MuSK and anti-LRP4 subtypes accounting for the remainder. An estimated 7,000–10,000 UK patients have generalised MG (gMG); diagnosis is confirmed via AChR-Ab testing at routine NHS immunology labs available at every NHS trust, with anti-MuSK and anti-LRP4 testing reserved for specialist neuromuscular labs. The NHS neuromuscular network comprises approximately 30 specialist centres coordinated through the Muscular Dystrophy UK (MDUK) network, and the Myasthenia Gravis Association UK (MGA) maintains a patient registry of roughly 3,000 enrolled members.
Eculizumab's own MG appraisal (TA636) was terminated in 2020 after the manufacturer chose not to submit a cost-effectiveness dossier, so NICE never modelled a cost-per-QALY figure for eculizumab in MG. Efgartigimod's appraisal (NICE technology appraisal GID-TA10986, project ID4003) concluded with final guidance TA1069, published 4 June 2025: NICE does not recommend efgartigimod for NHS use, citing gaps and uncertainties in the cost-effectiveness evidence. As a result, an estimated 4,000 UK moderate-to-severe gMG patients remain on the pyridostigmine plus corticosteroid/azathioprine/mycophenolate backbone, with IVIg or plasma exchange reserved for crises; patients who started efgartigimod on the NHS before June 2025 continue under transitional funding. MGA UK survey data estimate that 30–40% of UK gMG patients have inadequate disease control on current standard therapy, the population a future efgartigimod resubmission or new entrant would need to address.
UK gMG treatment landscape — the immunosuppressive backbone and the FcRn antagonist's NICE rejection
| Drug | Class | Company | MHRA/NICE Status | Key Evidence |
|---|---|---|---|---|
| Vyvgart (efgartigimod alfa) | FcRn antagonist, IV/SC | argenx | MHRA approved March 2023; NICE TA1069 not recommended, June 2025 — pre-guidance NHS starts continue | ADAPT trial: 68% MG-ADL responder |
| Mestinon + IST (pyridostigmine + azathioprine/MMF) | AChE inhibitor + immunosuppression | Generic | NHS formulary standard of care — no NICE-recommended novel-agent commissioning | 85%+ of UK gMG patients on this backbone |
Sources: NICE TA1069 (efgartigimod, June 2025); MGA UK survey 2023; NICE TA636 (eculizumab, terminated 2020); ADAPT trial evidence.
What this assessment answers
Every section answers a named commercial question your team is asking, scoped to your asset.
- What is the size of the UK gMG population with inadequate disease control on standard therapy, and how does this segment map to efgartigimod's June 2025 NICE rejection (TA1069)? • UK gMG population sizing by AChR/MuSK/LRP4 serological status • inadequate-control segment sizing (MGA UK survey data) • addressable population for FcRn antagonism following NICE TA1069
- What is the NHS diagnostic pathway for MG, and how does thymoma screening and thymectomy factor into treatment decisions for AChR+ patients? • NHS serological testing algorithm (AChR-Ab, anti-MuSK, single-fibre EMG) • CT thorax thymoma screening pathway • thymectomy eligibility per MGTX trial evidence and NHS thoracic surgery capacity
- Why was eculizumab's MG appraisal withdrawn and efgartigimod rejected by NICE, and what does this precedent mean for the next agent's cost-effectiveness case at NICE's QALY threshold? • NICE eculizumab MG appraisal termination context (TA636, 2020, no dossier submitted) • efgartigimod TA1069 evidence base and committee rationale (ADAPT trial, rejected June 2025) • cost-effectiveness positioning against the immunosuppressive backbone
What's inside
-
1 · Disease Biology & Serological Subtypes 4 pp
- Why AChR antibodies drive 85% of generalised MG cases, with anti-MuSK and anti-LRP4 accounting for the remainder
- How serological subtype determines the diagnostic testing pathway and treatment eligibility
-
2 · UK gMG Epidemiology & NHS Neuromuscular Network 5 pp
- Sizing the 7,000-10,000 UK gMG population against the roughly 30-centre NHS neuromuscular network coordinated through MDUK
- How the Myasthenia Gravis Association UK patient registry of roughly 3,000 enrolled members supports population tracking
-
3 · NHS Diagnostic Pathway & Thymoma Screening 4 pp
- The AChR-Ab, anti-MuSK, and single-fibre EMG testing algorithm from routine NHS labs to specialist neuromuscular labs
- CT thorax thymoma screening and thymectomy eligibility per MGTX trial evidence for AChR-positive patients
-
4 · Standard-of-Care Backbone & the Treatment Gap 5 pp
- The pyridostigmine-plus-corticosteroid/azathioprine/mycophenolate backbone that over 85% of UK gMG patients remain on
- Why 30-40% of UK gMG patients report inadequate disease control despite this standard therapy, per MGA UK survey data
-
5 · NICE Precedent — Eculizumab's Withdrawn Appraisal & Efgartigimod's TA1069 Rejection 4 pp
- Why eculizumab's TA636 appraisal was terminated in 2020 without a submitted cost-effectiveness dossier
- How NICE's June 2025 TA1069 verdict on efgartigimod cited evidence gaps despite a 68% MG-ADL responder rate in ADAPT
-
6 · Access Outlook & Commercial Implications 4 pp
- What pre-guidance NHS efgartigimod patients continuing under transitional funding signal for a future resubmission
- The addressable population and cost-effectiveness case a next entrant would need to build against the immunosuppressive backbone
Appendix and source ledger included · 45-minute analyst readout included with delivery
Custom assessment delivered in 72 hours.
Assess this reportIncluded with every brief
Get Started
Commission this assessment
AXLRx Myasthenia Gravis Disease Landscape is built for commercial, medical affairs, and market access teams that need a rigorous, evidence-based characterisation of the UK gMG patient population and the NHS access pathway following efgartigimod's NICE rejection (TA1069). Custom assessment in 72 hours.
- 1. Submit your requestSpecify indication, geography, and epidemiological focus.
- 2. Scoping callAXLRx analyst confirms subpopulation scope, data sources, and delivery format.
- 3. DeliveryResearch-verified assessment in 72 hours with optional analyst readout.
How AXLRx builds this assessment
Prepared by MoatRx analysts on the AXLRx commercial consulting engine.
UK myasthenia gravis disease landscape is built from Myasthenia Gravis Association UK (MGA) survey and registry data, MDUK neuromuscular network centre mapping, and NICE appraisal documentation for both efgartigimod (TA1069, not recommended) and eculizumab (TA636, terminated) — the two data points that frame UK gMG's NICE cost-effectiveness precedent.
Key sources: MGA UK annual report 2023; MDUK neuromuscular network centre data; NICE MG guideline scope 2024; NHS MG management protocol (British Society of Immunology); NICE TA1069 (efgartigimod, June 2025); NICE TA636 (eculizumab, terminated 2020). All figures carry source citations and are triangulated across multiple primary sources.
- UK gMG population estimate verified against MGA UK annual report 2023
- NHS diagnostic pathway and thymectomy eligibility verified against NICE MG guideline scope 2024 and NHS MG management protocol (British Society of Immunology)
- Inadequate disease control rate (30–40%) verified against MGA UK survey 2023
- Eculizumab appraisal termination and efgartigimod NICE rejection verified against the published NICE TA636 (2020) and NICE TA1069 (June 2025) guidance documents
Frequently asked questions
Deliverables What formats are included with every assessment?
Every commissioned assessment includes three deliverables: a 20–30 page PDF analyst assessment with verified sources and exhibit tables, an editable Excel model (drug comparison grid, payer formulary data, or patient flow model — depending on deliverable type), and a 10–15 slide PowerPoint readout deck formatted for commercial team presentations. An optional 60-minute analyst readout call is included with all deliveries.
Sources What sources does AXLRx use, and how are findings verified?
AXLRx builds from primary sources only: patient-organisation annual reporting, neuromuscular network centre data, the NICE myasthenia gravis guideline scope, national management protocols, and NICE technology appraisal records including one terminated appraisal. No secondary summaries or market research reports. Every factual claim is independently verified before inclusion. Source citations are provided for all key data points in the delivered assessment.
Customisation Can I tailor the assessment to my specific question, geography, or comparator set?
Yes. The intake form captures your indication, target geography, key comparator drugs, and the specific commercial question you need answered. A scoping call confirms scope before research starts. Custom extensions (additional payer markets, pipeline agent profiles, or country-specific deep-dives) can be added to any standard assessment. Commission via the intake form to start.